Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Metabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM.

BMC cancer - 8 Feb 2018

Mörén Lina, Perryman Richard, Crook Tim, Langer Julia K, Oneill Kevin, Syed Nelofer, Antti Henrik

Abstract excerpt

BACKGROUND: Tumour cells have a high demand for arginine. However, a subset of glioblastomas has a defect in the arginine biosynthetic pathway due to epigenetic silencing of the rate limiting enzyme argininosuccinate synthetase (ASS1). These tumours are auxotrophic for arginine and susceptible to the arginine degrading enzyme, pegylated arginine deiminase (ADI-PEG20). Moreover, ASS1 deficient GBM have a worse...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Argininosuccinate Synthase
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Glioblastoma

Share to Metabolomics

Share to Phenotype

Source

Open in PubMed Open full text

Identifiers

PMID: 29422017
DOI: 10.1186/s12885-018-4040-3
PMCID: PMC5806242

Genes

ASS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Metabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM.PMID 29422017Read ↗

ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance.Semantic proximity Read ↗

Methodological Approaches for Assessing Metabolomic Changes in Glioblastomas.Semantic proximity Read ↗

A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade GliomaSemantic proximity Read ↗

Integrated metabolomics and transcriptomics analysis of monolayer and neurospheres from glioblastoma cellsSemantic proximity Read ↗

Targeting distinct amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomas.Semantic proximity Read ↗

Glioblastoma multiforme: Metabolic differences to peritumoral tissue and IDH-mutated gliomas revealed by mass spectrometry imaging.Semantic proximity Read ↗

Metabolomics profiling in plasma samples from glioma patients correlates with tumor phenotypes.Semantic proximity Read ↗

Anion-exchange chromatography mass spectrometry provides extensive coverage of primary metabolic pathways revealing altered metabolism in IDH1 mutant cells.Semantic proximity Read ↗

Metabolic checkpoint CPS1 sustains TCA anaplerosis via urea cycle in IDH-mutant gliomas.Semantic proximity Read ↗

A Phase II Trial of ADI-PEG20 in Combination with Gemcitabine and Docetaxel for the Treatment of Soft Tissue SarcomaSemantic proximity Read ↗

Comprehensive Metabolic Profiling of MYC-Amplified Medulloblastoma Tumors Reveals Key Dependencies on Amino Acid, Tricarboxylic Acid and Hexosamine PathwaysSemantic proximity Read ↗

Diagnosis of adenylosuccinate lyase deficiency by metabolomic profiling in plasma reveals a phenotypic spectrumSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.